Therapeutic Group

Indication Dosage

Newly Diagnosed Multiple Myeloma In Patients Who Have Undergone Autologous Stem Cell Transplantation: 

• Adult: 10 Mg Once Daily For 28 Consecutive Days Of Repeated 28-day Cycles; Increased If Tolerated To 15 Mg Once Daily, After 3 Cycles 

Newly Diagnosed Multiple Myeloma In Patients Not Eligible For Transplant (in Combination With Dexamethasone), Multiple Myeloma With Prior Therapy (in Combination With Dexamethasone): 

• Adult: 25 Mg Once Daily For 21 Consecutive Days Of Repeated 28-day Cycles, For Doses Of Dexamethasone, For Dose Adjustments Due To Side-effects Consult Product Literature 

Newly Diagnosed Multiple Myeloma In Patients Not Eligible For Transplant (in Combination With Melphalan And Prednisone): 

• Adult: 10 Mg Once Daily For 21 Consecutive Days Of Repeated 28-day Cycles For Up To 9 Cycles, Patients Who Complete 9 Cycles Or Are Intolerant To Combination Therapy Should Continue Treatment With Lenalidomide As Monotherapy. 

Newly Diagnosed Multiple Myeloma In Patients Not Eligible For Transplant (in Combination With Bortezomib And Dexamethasone): 

• Adult: 25 Mg Once Daily For 14 Consecutive Days Of Repeated 21-day Cycles For Up To 8 Cycles, Followed By 25 Mg Once Daily For 21 Consecutive Days Of Repeated 28-day Cycles (in Combination With Dexamethasone Alone), For Doses Of Bortezomib And Dexamethasone, For Dose Adjustments Due To Side-effects Consult Product Literature 

Myelodysplastic Syndromes: 

• Adult: 10 Mg Once Daily For 21 Consecutive Days Of Repeated 28-day Cycles. 

Mantle Cell Lymphoma: 

• Adult: 25 Mg Once Daily For 21 Consecutive Days Of Repeated 28-day Cycles.

Content

Pregnancy

Contraindicated

Stability

Contra Indications

Precautions

Lactation

Side Effects